Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
16(64%)
Results Posted
0%(0 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_2
6
24%
Ph phase_1
6
24%
Ph phase_3
13
52%

Phase Distribution

6

Early Stage

6

Mid Stage

13

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
6(24.0%)
Phase 2Efficacy & side effects
6(24.0%)
Phase 3Large-scale testing
13(52.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

16

trials recruiting

Total Trials

25

all time

Status Distribution
Active(21)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Recruiting16
Not yet recruiting5
unknown2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
16
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (24.0%)
Phase 26 (24.0%)
Phase 313 (52.0%)

Trials by Status

unknown28%
completed14%
recruiting1664%
terminated14%
not_yet_recruiting520%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT07544056Phase 2

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Not Yet Recruiting
NCT06828354Phase 3

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Recruiting
NCT07533123Phase 3

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Recruiting
NCT05516914Phase 1

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Completed
NCT07111546Phase 2

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Recruiting
NCT06821503Phase 1

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Recruiting
NCT07424287Phase 3

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Not Yet Recruiting
NCT07418749Phase 3

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Not Yet Recruiting
NCT06752811Phase 3

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

Recruiting
NCT07398339Phase 2

Cosiporfin Sodium for Injection Photodynamic Therapy

Recruiting
NCT07229625Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Recruiting
NCT07229586Phase 1

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Recruiting
NCT06929624Phase 3

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Recruiting
NCT06079983Phase 3

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Recruiting
NCT07151872Phase 2

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not Yet Recruiting
NCT06738251Phase 3

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting
NCT06892431Phase 2

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not Yet Recruiting
NCT06792253Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
NCT06143553Phase 3

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recruiting
NCT06685796Phase 2

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
25